

part 95 #10

FORM PTO-1449D  
(REV. 7-80)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.  
210121.427C23

APPLICATION NO.  
09/759,143

**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT**

(Use several sheets if necessary)

APPLICANTS  
Jiangchun Xu et al.

FILING DATE  
January 12, 2001

GROUP ART UNIT  
1645

RECEIVED  
MAY 20 2002  
TECH CENTER 1600/2500  
FILING DATE  
IF APPROPRIATE

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
12	AK	WO 01/51633	07/19/01	WIPO ✓		
	AL	WO 98/37039	08/27/98	WIPO		X
	AM					
	AN					
	AO					

**OTHER PRIOR ART** (Including Author, Title, Date, Pertinent Pages, Etc.)

	AP	
	AQ	
	AR	

EXAMINER

*[Signature]*

DATE CONSIDERED

6/10/03

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
210121.427C23EXPRESS MAIL NO.  
EL615487784US

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS  
Jiangchun Xu et al.FILING DATE  
December 20, 2000

GROUP ART UNIT

10944 U.S. PAT.  
09/759143  
01/12/01

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA	5,786,148	07/28/98	Bandman et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
<del>AB</del>	<del>DE 19649207</del>	<del>11/27/96</del>	<del>Germany</del>			X
AC	EP 317 141 A2	05/24/89	EPO			
AD	EP 652 014 A1	5/10/95	EPO			
<del>AE</del>	<del>EP 936 270 A2</del>	<del>08/18/99</del>	<del>EPO</del>			X
AF	WO 93/14755	08/05/93	PCT			
AG	WO 93/25224	12/23/93	PCT			
AH	WO 94/09820	05/11/94	PCT			


## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AI	Ahn and Kunkel, "The structural and functional diversity of dystrophin," <i>Nature Genetics</i> 3: 283-291, April, 1993.
AJ	Alexeyev et al., "Improved antibiotic-resistance gene cassettes and omega elements for <i>Escherichia coli</i> vector construction and in vitro deletion/insertion mutagenesis," <i>Gene</i> 160:63-67, 1995.
AK	Berthon et al., "Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43," <i>Am. J. Hum. Genet.</i> 62(6):1416-1424, June 1998.
AL	Blok et al., "Isolation of cDNA that are differentially expressed between androgen-dependent and androgen-independent prostate carcinoma cells using differential display PCR," <i>The Prostate</i> 26:213-224, 1995.
AM	Busselmakers et al., Genbank Accession No. AF103907, August 14, 2000.
AN	Busselmakers et al., Genbank Accession No. AF103908, August 14, 2000.
AO	Cawthon et al., "cDNA sequence and genomic structure of EVI2B, a gene lying within an intron of the neurofibromatosis type 1 gene," <i>Genomics</i> 9:446-460, 1991.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.427C23		EXPRESS MAIL NO. EL615487784US	
<b>INFORMATION DISCLOSURE STATEMENT</b> <i>(Use several sheets if necessary)</i>				APPLICANTS Jiangchun Xu et al.			
				FILING DATE December 20, 2000		GROUP ART UNIT	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
2	BA	WO 95/04548	02/16/95	PCT			
<del>1</del>	<del>BB</del>	<del>WO 95/14772</del>	<del>06/01/95</del>	<del>PCT (Cover page with English abstract only)</del>			<del>X</del>
2	BC	WO 95/30758	11/16/95	PCT			
1	BD	WO 96/21671	07/18/96	PCT			
1	BE	WO 97/33909	09/18/97	PCT			
1	BF	WO 98/12302	03/26/98	PCT			
1	BG	WO 98/17687	04/30/98	PCT			
2	BH	WO 98/20117	05/14/98	PCT			
<b>OTHER PRIOR ART</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
2	BI	Chu et al., "CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity," <i>J. Exp. Med.</i> 186(10): 1623-1631, November 17, 1997.					
1	BJ	Coleman et al., <i>Fundamental Immunology</i> , Wm. C. Brown Publishers, Dubuque, Iowa, 1989, pp. 465-466.					
1	BK	Database EMBL Accession No. AA453562, June 11, 1997, Hillier et al., "Homo sapiens cDNA clone 788180."					
1	BL	Derwent Geneseq Database, Accession No. V58522, December 8, 1998.					
1	BM	Derwent Geneseq Database, Accession No. V61287, January 6, 1999.					
1	BN	Duerst and Nees, "Nucleic acid characteristic of late or early passage cells immortalized by papilloma virus-and related polypeptide(s) and antibodies, used for diagnosis and treatment of cervical cancer and assessing potential for progression of cervical lesions," Derwent World Patent Index, Accession No. 1998-121623, 1998. See also German Patent DE 19649207 C1.					
2	BO	El-Shirbiny, "Prostatic Specific Antigen, <i>Advances In Clinical Chemistry</i> 31:99-133, 1994.					
EXAMINER				DATE CONSIDERED			
				6/11/03			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
210121.427C23EXPRESS MAIL NO.  
EL615487784US

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS  
Jiangchun Xu et al.FILING DATE  
December 20, 2000

GROUP ART UNIT

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
----------------------	-----------------	------	------	-------	----------	-------------------------------

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
12	CA	WO 98/31799	07/23/98	PCT		
	CB	WO 98/37093	08/27/98	PCT		
	CC	WO 98/37418	08/27/98	PCT		
	CD	WO 98/38310	09/03/98	PCT		
	CE	WO 98/39446	09/11/98	PCT		
	CF	WO 98/45435	10/15/98	PCT		
	CG	WO 98/50567	11/12/98	PCT		
	CH	WO 99/06548	02/11/99	PCT		

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

12	CI	Ezzell, C., "Cancer vaccines: an idea whose time has come?" <i>The Journal of NIH Research</i> 7:46-49, January, 1995.
	CJ	Hara et al., "Characterization of cell phenotype by a novel cDNA library subtraction system: expression of CD8 $\alpha$ in a mast cell-derived interleukin-4-dependent cell line," <i>Blood</i> 84(1):189-199, July 1, 1994.
	CK	Harris et al., "Polycystic Kidney Disease 1: identification and analysis of the primary defect," <i>J. Am. Soc. of Nephrol.</i> 6:1125-1133, 1995.
	CL	Hillier et al., Genbank Accession No. AA100799, December 23, 1997.
	CM	Hillier et al., Genbank Accession No. R20590, April 18, 1995.
	CN	Hudson, T., Genbank Accession No. G22461, May 31, 1996.
12	CO	Kroger, B. "New serine protease form human prostate, useful for identifying specific inhibitors, antibodies and probes," Derwent World Patent Index, Accession No. 99-432218, 1999. See also European Patent EP 936 270 A2.


EXAMINER




DATE CONSIDERED



6/11/03

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.427C23		EXPRESS MAIL NO. EL615487784US	
<b>INFORMATION DISCLOSURE STATEMENT</b> <i>(Use several sheets if necessary)</i>				APPLICANTS Jiangchun Xu et al.			
				FILING DATE December 20, 2000		GROUP ART UNIT	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
2	DA	WO 99/06552	02/11/99	PCT			
2	DB	WO 99/25825	05/27/99	PCT			
2	DC	WO 99/31236	06/24/99	PCT			
	DD						
<b>OTHER PRIOR ART</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
2	DE	Lalvani et al., "Rapid effector function in CD8 <sup>+</sup> memory cells," <i>J. Exp. Med.</i> 186(6):859-865, September 15, 1997.					
	DF	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA551449, September 5, 1997.					
	DG	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA551759, August 11, 1997.					
	DH	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA631143, October 31, 1997.					
	DI	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA653016, November 25, 1997.					
	DJ	Nelson et al., Genbank Accession No. NP_004908, March 18, 2000.					
	DK	Robson et al., "Identification of prostatic adrogen regulated genes using the differential display technique," <i>Proceeding of the American Association for Cancer Research Meeting</i> 86, 36: p.266, Abstract No. 1589, 1995.					
	DL	Schena et al., "Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes," <i>Proc. Natl. Acad. Sci. USA</i> 93(19):10614-10619, September 17, 1996.					
2	DM	Sherman et al., "Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8," <i>Science</i> 258(5083):815-818, October 30, 1992.					
EXAMINER 				DATE CONSIDERED 6/11/03			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.427C23		EXPRESS MAIL NO. EL615487784US	
<b>INFORMATION DISCLOSURE STATEMENT</b> <i>(Use several sheets if necessary)</i>				APPLICANTS Jiangchun Xu et al.			
				FILING DATE December 20, 2000		GROUP ART UNIT	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	EA						
	EB						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	EC						
<b>OTHER PRIOR ART</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	EF	Short et al., "λ ZAP: a bacteriophage λ expression vector with <i>in vivo</i> excision properties," <i>Nucleic Acids Research</i> 16(15):7583-7600, 1988.					
	EG	Sjögren, H., "Therapeutic Immunization Against Cancer Antigens Using Genetically Engineered Cells," <i>Immunotechnology</i> 3: 161-172, 1997.					
	EH	Smith et al., "Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search," <i>Science</i> 274(5291), 1371-1374, November 22, 1996.					
	EI	Theobald, et al., "Targeting p53 as a general tumor antigen," <i>Proc. Natl. Sci. USA</i> 92(25):11993-11997, December 5, 1995.					
	EJ	Tusnady and Simon, "Principles governing amino acid compositions of integral membrane proteins: application to topology prediction," <i>J. Mol. Biol.</i> 283(2):489-506, October 23, 1998.					
	EK	Van Tsai et al., "In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells," <i>Critical Reviews in Immunology</i> 18:65-75, 1998.					
	EL	Vasmatzis et al., "Discovery of three genes specifically expressed in human prostate by expressed sequence tag database analysis," <i>Proc. Natl. Acad. Sci. USA</i> 95(1):300-304, January 6, 1998.					
	EM	Yee et al., "Isolation of tyrosinase-specific CD8 <sup>+</sup> and CD4 <sup>+</sup> T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus," <i>The Journal of Immunology</i> 157(9):4079-4086, November 1, 1996.					
	EN	Zitvogel et al., "Eradication of Established Murine Tumors Using a Novel Cell-Free Vaccine: Dendritic Cell-Derived Exosomes," <i>Nature Medicine</i> 4(5): 594-600, May, 1998.					
EXAMINER				DATE CONSIDERED			
				6/11/03			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449  
(REV.7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
210121.427C23APPLICATION NO.  
09/759,143SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS  
Jiangchun Xu et al.FILING DATE  
January 12, 2001GROUP ART 1  
1645

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
AK	WO 00/04149	1/27/00	WIPO ✓		
AL	WO 01/25272	4/12/01	WIPO		
AM	WO 01/34802	5/17/01	WIPO ✓		
AN					
AO					

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AP	
AQ	
AR	

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).